Cart
sales@molnova.com
Lodoxamide ethyl
CAS No. 53882-13-6
Lodoxamide ethyl( —— )
Catalog No. M36189 CAS No. 53882-13-6
lodoxamide ethyl is a new orally active anti-allergic compound for the prevention of antigen-induced bronchoconstriction and blockage of skin allergic reactions.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 129 | Get Quote |
|
| 5MG | 200 | Get Quote |
|
| 10MG | 295 | Get Quote |
|
| 25MG | 539 | Get Quote |
|
| 50MG | 718 | Get Quote |
|
| 100MG | 981 | Get Quote |
|
| 500MG | 1962 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLodoxamide ethyl
-
NoteResearch use only, not for human use.
-
Brief Descriptionlodoxamide ethyl is a new orally active anti-allergic compound for the prevention of antigen-induced bronchoconstriction and blockage of skin allergic reactions.
-
Descriptionlodoxamide ethyl is a new orally active anti-allergic compound for the prevention of antigen-induced bronchoconstriction and blockage of skin allergic reactions.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number53882-13-6
-
Formula Weight367.74
-
Molecular FormulaC15H14ClN3O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(C(OCC)=O)=O)C1=C(Cl)C(NC(C(OCC)=O)=O)=CC(C#N)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Ro 5212773
EPPTB is a selective TAAR1 antagonist.
-
Pachypodol
Pachypodol has antibacterial and antifungal activities against Bacillus subtilis, Staphylococcus aureus, Staphylococcus faecalis, Echerichia coli, Pseudomonas aeruginosa, Candida albicans, Candida krusei and Candida galabrata.
-
Simlukafusp alfa
Simlukafusp alfa (FAP-IL2v) is a tumor-targeting immune cytokine, a human IgG1 antibody, with antitumor activity and immunostimulatory properties that potentiate in vitro and in vivo activity of therapeutic antibodies mediating antibody-dependent or T-cell-independent cytotoxicity (TDCC) and programmed death ligand 1 (PD-L1) checkpoint inhibition.
